hiPSC-Derived Bone Marrow Milieu Identifies a Clinically Actionable Driver of Niche-Mediated Treatment Resistance in Leukemia

Scientists developed hiPSC-engineered niches to reveal druggable cancer-niche dependencies. They revealed that mesenchymal and vascular niche-like hiPSC-derived cells supported ex vivo proliferation of patient-derived leukemia cells, affect dormancy, and mediated treatment resistance.